Skip to main content
Show full summary

Question HL2997: tabled on 22 April 2020 and due for answer by 6 May 2020

This type of business sits within the Questions & Statements category.

This question has been answered by the relevant Government Department.

Question text

To ask Her Majesty's Government further to the Written Answer by {member id="4708" field="DisplayAs"}{/member} on 21 April (HL2602), why they have not been in contact with the National Cancer Institute Pascale Foundation or the Colli Hospital in Italy to assess the potential outcomes of the use of Tocilizumab to treat patients with COVID-19 related pneumonia; how they are monitoring “the results of trials of experimental therapies for COVID-19 from around the world”; what discussions they plan to have with the National Cancer Institute Pascale Foundation, and the Colli Hospital in Italy as part of that monitoring; whether the United Kingdom Therapeutics Task Force will report on its findings of its assessment of tocilizumab; and if so, when.
Legend for business item text
Item that is new or altered.
[I] Indicates that the member concerned has a relevant registered interest.
* Item is an oral question.
Numbers starting HL are unique identifiers for written questions, Bills or papers.

Member's Registered Interests

There are no interests to show.